Literature DB >> 20524784

Bacterial pneumonia following cytotoxic chemotherapy for lung cancer: clinical features, treatment outcome and prognostic factors.

Seung Soo Yoo1, Seung-Ick Cha, Kyung-Min Shin, Shin-Yup Lee, Chang-Ho Kim, Jae-Yong Park, Tae-Hoon Jung.   

Abstract

Data regarding treatment outcomes and prognosis in pneumonia that occurs after lung cancer chemotherapy are lacking. We performed a retrospective study of 84 patients with clinically suspected bacterial pneumonia after cytotoxic chemotherapy for lung cancer. Small cell carcinoma was the most common histological type (36.9%, n = 31), followed by squamous cell carcinoma (35.7%, n = 30) and adenocarcinoma (21.4%, n = 18). The most frequent pathogen was Streptococcus pneumoniae (n = 14), followed by Klebsiella pneumoniae (n = 10), Staphylococcus aureus (n = 8), and Pseudomonas aeruginosa (n = 7). Of 84 patients, treatment outcome was determined for 80; the outcome was success in 52 (61.9%) and failure in 28 (33.3%); outcome remained undetermined for 4 patients (4.8%). Based on multivariate analysis, tachypnoea (respiratory rate ≥20/min) was the only significant predictor of treatment failure (odds ratio 4.79, 95% confidence interval 1.17-19.70; p = 0.030). In conclusion, bacterial pneumonia after cytotoxic chemotherapy for lung cancer was found to be caused more often by S. pneumoniae and K. pneumoniae than P. aeruginosa, and treatment failure leading to death was found to be high. Tachypnoea was independently associated with treatment failure in this population.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20524784     DOI: 10.3109/00365548.2010.489569

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  2 in total

Review 1.  Bacterial Pneumonia in Patients with Cancer: Novel Risk Factors and Management.

Authors:  Justin L Wong; Scott E Evans
Journal:  Clin Chest Med       Date:  2017-03-01       Impact factor: 2.878

2.  Colonization with multi-drug-resistant organisms negatively impacts survival in patients with non-small cell lung cancer.

Authors:  Jan A Stratmann; Raphael Lacko; Olivier Ballo; Shabnam Shaid; Wolfgang Gleiber; Maria J G T Vehreschild; Thomas Wichelhaus; Claudia Reinheimer; Stephan Göttig; Volkhard A J Kempf; Peter Kleine; Susanne Stera; Christian Brandts; Martin Sebastian; Sebastian Koschade
Journal:  PLoS One       Date:  2020-11-25       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.